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Summary
Antiosteoporotic drugs are recommended in patients with
fragility fractures and in patients considered to be at high
fracture risk on the basis of clinical risk factors and/or low
bone mineral density. As first-line treatment most patients
are started with an antiresorptive treatment, i.e. drugs that
inhibit osteoclast development and/or function (bisphos-
phonates, denosumab, oestrogens or selective oestrogen
receptor modulators). In the balance between benefits and
risks of antiresorptive treatment, uncertainties remain re-
garding the optimal treatment duration and the manage-
ment of patients after drug discontinuation. Based on the
available evidence, this position statement will focus on
the long-term management of osteoporosis therapy, for-
mulating decision criteria for clinical practice.
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Introduction
Osteoporosis is a chronic metabolic disease characterised
by a progressive loss of bone mass and microarchitectural
deterioration, ultimately resulting in an increased risk of
fragility fractures. During recent decades remarkable ad-
vances have been made in the diagnosis and treatment of
osteoporosis. Specifically, and based on the understanding
of the pathogenesis of osteoporosis, new treatment options
including antiresorptive and anabolic treatment modalities
have been developed and introduced into clinical routine.
In treatment guidelines, antiosteoporotic drugs are recom-
mended for patients with vertebral or nonvertebral low-
trauma fractures and for patients who present with a high
fracture risk based on clinical risk factors and/or low bone
mineral density (BMD) [1]. As first-line treatment, most
patients are started with an antiresorptive treatment, i.e.,
a drug that inhibit osteoclast development and/or function
(bisphosphonates, denosumab or selective oestrogen re-
ceptor modulators [SERMs]). In younger women up to
the age of 60 years or up to 10 years after menopause,
menopausal hormone therapy is recommended [2]. Its frac-
ture preventive effect has been shown to be significant
in postmenopausal women, even those without increased
fracture risk [3]. In this age group, no long-term data are
available for the nonhormonal antiresorptive alternatives
[2]. In the balance between benefits and risks of antiresorp-
tive treatment, uncertainties remain regarding the optimal
treatment duration and the management of patients after
drug discontinuation.
Alternatively, teriparatide, a recombinant human parathy-
roid hormone analogue, increases the formation of new
bone substance by virtue of its stimulating effects on os-
teoblasts [4]. In Switzerland, teriparatide is approved for
second-line treatment in patients with progressive osteo-
porosis or glucocorticoid-induced osteoporosis. However,
as a result of its pronounced anabolic effect, particularly at
cancellous bone sites (such as the vertebrae), its use as a
first-line treatment option is increasingly recommended in
patients at high fracture risk [5].
Based on the available evidence, this position statement
will focus on the long-term management of osteoporosis
therapy, formulating decision criteria for clinical practice.
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Treatment modalities and their mode of action
Bisphosphonates are pyrophosphate analogues that act
mainly by inhibiting osteoclast-mediated bone resorption.
They are characterised by a high affinity with bone and a
long half-life within the skeleton [6, 7]. The identification
of the receptor activator of NF-κB ligand (RANKL) and
osteoprotegerin (OPG) as central regulators of bone me-
tabolism has resulted in the development of denosumab,
a human monoclonal antibody against RANKL. An un-
derstanding of its mode of action, as compared to that
of bisphosphonates, is essential to appreciate the differ-
ences in their use. Bisphosphonates accumulate on min-
eralised bone surface and are internalised by mature os-
teoclasts. Because of their long lasting retention on bone
surface (particularly so for alendronate and zoledronate),
bisphosphonates have a unique residual treatment effect
on bone resorption even after treatment discontinuation. In
contrast, circulating denosumab inhibits the maturation of
osteoclasts by binding to and inhibiting RANKL. Thereby
the effect of denosumab is limited to the period of drug ex-
posure, i.e., the duration of treatment [8]. Importantly, dis-
continuation of denosumab is associated with a significant
bone turnover rebound and a rapid loss of bone mass [9,
10], a phenomenon that has not been observed after dis-
continuation of bisphosphonates [7].
The effect of menopausal hormone therapy on bone me-
tabolism ends with the cessation of oestrogen administra-
tion. However, a long lasting decrease of fracture risk has
been confirmed for all major fractures up to 16 years after
discontinuation of hormone therapy [3, 11–13]. To reach
this protective effect, the number needed to treat (NNT) is
7 [11].There is no reason to place mandatory limits on the
duration of menopausal hormone therapy. Data from the
WHI trial and other studies support safe use for at least 5
years in healthy women starting treatment before the age
of 60 [2].
The mode of action of teriparatide is related to its ability to
stimulate processes associated with bone formation, which
are then coupled to processes associated with bone resorp-
tion, leading to an overall increase in bone remodelling,
but with a positive balance towards bone formation [14].
The bone formation induced by teriparatide not only in-
creases bone mass but also improves the microarchitecture
of the skeleton, primarily the trabecular and cortical thick-
ness, thereby leading to improved strength and increased
mechanical resistance. However, teriparatide also increas-
es intracortical bone remodelling, leading to some porosity,
which may partly explain the transient decline of BMD at
predominantly cortical bone sites (such as the distal radius
and femoral neck). As for many antiresorptive agents (ex-
cept for bisphosphonates), effects of teriparatide on bone
turnover are transient and limited to the time of expo-
sure. Hence, sequential therapy with antiresorptive drugs is
needed to improve secondary mineralisation and maintain
bone mass [15, 16].
Duration of treatment
Benefits and safety during long-term-treatment
There is consensus that patients with high fracture risk
should receive pharmacological treatment to prevent
fragility fractures. The decision for how long to treat with
antiresorptive drugs is largely dependent on their long-
term efficacy and safety.
A network meta-analysis of several pharmacological
agents available for the prevention of fragility fractures
found strong evidence to support the efficacy of bispho-
sphonates (alendronate, risedronate, zoledronate), deno-
sumab and teriparatide in reducing the relative risk of ver-
tebral fractures by 40–70% and nonvertebral fractures by
20–40% [17]. For antiresorptives, this translates into a
NNT of 15–25 to prevent one vertebral fracture over 3
years of treatment. However, one has to bear in mind that
the NNT depends largely on the fracture incidence in the
study population, with a lower NNT in high risk patients.
Data on fracture risk reduction during long-term treatment
are mainly available for antiresorptive drugs. Indeed, the
use of teriparatide as an anabolic drug is limited to 24
months duration. Among antiresorptives, the results of ex-
tension studies with alendronate, risedronate and zole-
dronate have been analysed. Postmenopausal women treat-
ed with alendronate for 4 to 5 years in the Fracture In-
tervention Trial (FIT) were randomised to continue with
alendronate for 5 years or switched to placebo (FLEX
Study) [18]. Postmenopausal women who had already re-
ceived three annual intravenous infusions of zoledronate
(Horizon Study) were randomised to either continue with
yearly zoledronate or switch to placebo for another 3 years
(Horizon Study Extension) [19]. The results of the 10 years
of therapy with alendronate and the 6 years with zole-
dronate were a slight reduction in clinical and/or morpho-
metric vertebral fractures as compared with stopping alen-
dronate after 5 years or zoledronate after 3 years, since in
the latter case the incidence of vertebral fractures increased
again after discontinuation of therapy. In the FLEX study,
continuation of alendronate for 10 years instead of stop-
ping after 5 years decreased nonvertebral fractures only in
women whose femoral neck T-score was ˗2.5 standard de-
viations (SD) or less at the time of discontinuation. How-
ever, non-spine fracture incidence was similar in those who
continued 10 years alendronate or 6 years zoledronate,
compared with those who stopped active treatment during
the extension studies [20]. Notably, these extension studies
were not primarily designed for fracture outcomes, but to
look at BMD changes upon continuation or discontinuation
of therapy (BMD progressively declining upon treatment
cessation), and were also limited in the number of patients
who were enrolled long-term.
The antifracture efficacy data on long-term treatment with
denosumab, up to 10 years, are reported from the Exten-
sion study of the FREEDOM trial. In the open-label Exten-
sion study, 4550 postmenopausal women with osteoporo-
sis who previously received either denosumab (long-term
treatment group) or placebo (crossover group) were as-
signed to receive denosumab for another 7 years. After sig-
nificant reduction of vertebral and nonvertebral fractures
in the denosumab-treated group as compared with place-
bo during the FREEDOM study (first 3 years), the yearly
incidence of new vertebral fractures remained low, where-
as nonvertebral fractures further significantly decreased in
year 4 [21] and then remained stable (approximately 1.5%
per year for both vertebral and nonvertebral fractures in
years 4 to 10 of continuous therapy) [22].
In general, antiresorptive drugs have a good safety profile.
The side-effects vary between drugs, but many are as-
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sociated with gastrointestinal effects after intake of oral
bisphosphonates or influenza-like symptoms after intra-
venous bisphosphonate application (e.g., zoledronic acid).
Nevertheless, for bisphosphonates and denosumab rare but
serious adverse events have been reported, including os-
teonecrosis of the jaw (ONJ) and atypical femoral fractures
(AFF) [23]. ONJ is associated with oncology-dose par-
enteral antiresorptive therapy with bisphosphonates and
denosumab. The incidence of ONJ is greatest in the on-
cology patient population (1–15%), where high doses of
these medications are used at frequent intervals. In the os-
teoporosis patient population. However, the incidence of
ONJ is estimated to be 0.01 to 0.025%, and increases with
treatment duration. The incidence is marginally higher than
the incidence in the general population (<0.001%) [24].
Atypical femoral fractures located in the subtrochanteric
region and diaphysis of the femur have been reported in
patients taking bisphosphonates or denosumab, but are also
observed in individuals without specific bone medication.
The absolute risk of AFFs in patients on bisphosphonates
is extremely low, ranging from 3.2 to 50 cases per 100 000
person‐years [25]. However, long‐term use for more than 5
years may be associated with higher risk [26]. When bis-
phosphonates are stopped, risk of an AFF rapidly declines.
It is important to note that in treated women the absolute
risk for atypical fractures is up to 100-fold less than the risk
for hip fracture among untreated postmenopausal women
with high fracture risk [27].
Hence, for the efficacy of bisphosphonates and denosumab
to reduce hip fractures, the benefit-risk ratio of these drugs
remains favourable, particularly in patients at high fracture
risk.
For the decision about antiresorptive treatment duration in
an individual patient, reassessment of fracture risk is es-
sential. A patient is considered to remain at high risk of
fracture if they (a) experienced hip, spine or multiple os-
teoporotic fractures within 5 years before and/or during
therapy, (b) remain on continuous high fracture risk based
on clinical judgment or comorbidities, or (c) present with
persistent low BMD. Subgroup analyses of the extension
studies mentioned above indicate that patients whose
femoral neck (or total hip) BMD T-score remains below
˗2.5 SD after 5 years of therapy benefit most from contin-
uing antiresorptive therapy [21, 28–30]. As age and falls
are major risk factors for fracture, a T-score threshold of
˗2.0 SD for continuation of antiresorptive therapy seems
reasonable in older women (>65 years) and/or in frequent
fallers.
Management after discontinuation of therapy
As a rule, the effects of any drug vanish upon treatment
discontinuation, so that if the disease is chronic, symptoms
and complications will recur (e.g., high blood pressure and
risk of stroke upon cessation of antihypertensive medi-
cines, hyperglycaemia and related complications upon ces-
sation of antidiabetic drugs). The same is true for most
osteoporosis drugs, including oestrogens, SERMs, deno-
sumab and teriparatide. Bisphosphonates, because of their
high affinity for bone, remain in the skeleton even after the
drug is discontinued, which explains the slower and/or re-
tarded offset of effects, with a slight decrease in bone min-
eral density and increase in biochemical markers of bone
turnover, but to levels which can remain below pretreat-
ment levels for months to years [18, 19].
On the other hand, discontinuation of denosumab has been
associated with an increase of bone turnover markers to
above-baseline levels (rebound); these return to baseline
levels within 2 years of treatment cessation. In parallel,
BMD decreases to baseline levels within 1 to 2 years, re-
gardless of the duration of previous therapy [10]. Recent-
ly, after a few clinical cases of vertebral fractures were re-
ported upon cessation of denosumab therapy [31, 32], a
preliminary observation in more than 1000 subjects from
the FREEDOM study and its extension who discontinued
denosumab or placebo, indicated that vertebral fracture in-
cidence indeed increased nearly 4-fold within a year after
denosumab was stopped [33]. However, the absolute in-
cidence of vertebral fracture remained comparable to that
observed in subjects who discontinued placebo. Neverthe-
less, among subjects who sustained a new vertebral frac-
ture after discontinuing denosumab, the incidence of mul-
tiple new vertebral fractures tended to be higher than in
subjects who discontinued placebo [33]. Indirect compar-
ison of the FREEDOM results with those of the bisphos-
phonates extension studies (above) which showed that the
risk of vertebral fractures nearly doubles upon cessation of
bisphosphonate therapy, suggests that more patients may
sustain severe vertebral fractures when stopping denosum-
ab, which is consistent with the quick reversibility of its
antiresorptive effects. These observations led the medical
authorities in Switzerland, in agreement with the compa-
ny (Amgen) to adapt the drug label in order to warn pre-
scribers against the sudden interruption of denosumab and
the need to consolidate therapy with at least one year of a
non-reversible antiresorptive. Currently identified risk fac-
tors for vertebral fractures after discontinuation of deno-
sumab include prevalent fractures, BMD loss and longer
duration off therapy [32, 34]. In this context, it should be
noted that some data suggest that the rebound in bone re-
sorption and BMD can be avoided in patients previously
treated with bisphosphonates, probably due to their persis-
tence in bone tissue [35, 36].
Practical consequences
On the basis of the above mentioned data on the efficacy
and safety of antiresorptive drugs, we propose an approach
to aid decisions about the management of patients with os-
teoporosis on long-term therapy (fig. 1). Because the ex-
tension trials that suggested long-term anti-fracture effi-
cacy based on continuation vs discontinuation of therapy
were conducted exclusively in postmenopausal women,
the suggested approach is restricted to the management
of women with postmenopausal osteoporosis. Neverthe-
less, similar approaches in male osteoporosis seem rea-
sonable. Furthermore, the suggestions on long-term os-
teoporosis treatment modalities described below are not
evidence based, but represent interpretation of the current
data. Further studies are needed to elucidate antifracture ef-
ficacies of proposed sequential treatment algorithms.
1. Regular reassessment of fracture risk for decision of
treatment duration is essential. A patient is considered
to remain at high risk of fracture if any of the condi-
tions below is present:
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hip, spine or multiple osteoporotic fractures within 5
years before and/or during therapy;
high fracture risk score at baseline according to
FRAX® and/or continuously high fracture risk based
on clinical judgment or comorbidities (e.g., continuous
use of aromatase inhibitors for breast cancer, diabetes,
frailty);
persistent low BMD: on the basis of the above-men-
tioned extension trials (FLEX study, HORIZON- and
FREEDOM-Extension studies), patients with a T-score
persistently lower than ˗2.5 SD at the femoral neck (or
<˗2.0 SD in older patients and/or frequent fallers) ben-
efit the most from continuing therapy.
2. For postmenopausal women who have been on oral or
intravenous bisphosphonate therapy for 3 years (intra-
venous) to 5 years (oral), reassessment of individual
fracture risk is mandatory. In women at high risk (see
above), treatment should preferentially be switched to
denosumab, as comparison studies have shown supe-
riority of denosumab over bisphosphonates in treat-
ment-related changes in BMD [37]. For women with
an incident vertebral fracture bone-anabolic treatment
with teriparatide for 24 months is advised. Alternative-
ly, continuation of treatment for up to 10 years (oral
bisphosphonates) or 6 years (intravenous bisphospho-
nates) may be considered, depending on the risk (in-
creased risk of ONJ and AFF) and the benefit (fracture
risk reduction). In patients with low-to-moderate frac-
ture risk, a drug holiday is suggested with clinical, bio-
chemical and densitometric reassessment every 2 to 3
years.
3. For postmenopausal women who have been on treat-
ment with SERMs for 3 to 5 years and are considered
at high fracture risk (see above) switching treatment to
BPs or denosumab should be considered.
4. For postmenopausal women who have been on deno-
sumab therapy for at least 3 to 5 years, reassessment
of individual fracture risk is suggested. In women at
high risk (see above), continuation of treatment for up
to 10 years should be considered. Specifically, con-
tinuation of treatment is considered in women on an
aromatase inhibitor. In the case of very high fracture
risk (incident new vertebral fractures during denosum-
ab therapy), combination therapy, with teriparatide for
24 months followed by antiresorptive therapy, should
be considered on the basis of the favourable effects of
combination therapy on BMD, although evidence for
fracture risk reduction is lacking [38, 39].
5. In women with a favourable treatment response in
which denosumab therapy discontinuation is consid-
ered (low fracture risk, BMD increase into age-adjust-
ed range, cessation of aromatase inhibition), sequential
treatment with non-reversible antiresorptives (bispho-
sphonates, or SERMs in cases of bisphosphonate in-
tolerance) is mandatory, particularly in older women
with prevalent vertebral fractures and in women with-
out previous long-term therapy with one of the more
potent bisphosphonates (alendronate, zoledronate). Se-
quential therapy may be guided by the rebound in bone
turnover markers, particularly in patients with prior
bisphosphonate therapy [35, 39]. Treatment with non-
reversible antiresorptives may be needed for up to 12
to 24 months.
6. In patients suffering vertebral fractures after discon-
tinuation of denosumab, percutaneous vertebral ce-
ment augmentation should be used with caution as ver-
tebroplasty has been associated with a high number
of new vertebral fractures in these circumstances [31].
Pharmacological treatment should be restarted, either
with denosumab (eventually in combination with teri-
paratide) or zoledronate.
7. The anabolic effects of teriparatide on bone are tran-
sient and limited to the time of exposure. Sequential
therapy with antiresorptive drugs (bisphosphonates,
denosumab) drugs is mandatory to maintain bone mass
and improve secondary mineralisation.
Figure 1: Approach to the management of postmenopausal women on anti-osteoporotic therapy.1 High risk defined as (a) hip, spine or multi-
ple fractures before or during therapy; (b) femoral neck T-score <˗2.5 SD if age <65 years, <-2.0 SD if age >65 years and/or frequent falls; (c)
continuing hormone ablative therapy (e.g., aromatase inhibition, androgen deprivation therapy); (d) secondary osteoporosis, continuing gluco-
corticoid therapy.BP =bisphosphonate; Ca/VD = calcium and vitamin D supplementation; Dmab, denosumab; DXA = densitometry; SERM =
selective oestrogen receptor modulator; TPT = teriparatide
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8. When considering the duration of and options for os-
teoporosis treatment, the potential contributions of
poor compliance or adherence to therapy, inadequate
vitamin D status, high fall risk, or new risk factors
should be considered. Current guidelines recommend
that treatment of any osteoporotic drug should always
be supplemented with vitamin D at a dose of 800 IU
per day to ensure a replete vitamin D status. Advice on
an adequate calcium intake of 1000 mg per day from
nutritional sources is considered a basic strategy in
combination with osteoporotic drug treatment. If cal-
cium intake to a target range of 1000 mg cannot be
achieved through nutritional sources alone, a calcium
supplement of 300 to 500 mg/day is recommended.
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